Update: ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Lifts 2026 Outlook

MT Newswires Live

May 08

(Updates with share buyback program and stock movement in the last two paragraphs.)

ANI Pharmaceuticals (ANIP) reported Q1 adjusted earnings Friday of $2.05 per diluted share, up from $1.70 a year earlier.

Analysts surveyed by FactSet expected $1.30.

Net revenue for the quarter ended March 31 was $237.5 million, up from $197.1 million a year earlier.

Analysts polled by FactSet expected $207.6 million.

The company said it now expects full-year 2026 adjusted diluted EPS to be between $9.19 and $9.69, compared with its previous guidance for $8.83 to $9.34. Analysts surveyed by FactSet expect $9.07.

Full-year 2026 net revenue is now projected at $1.08 billion to $1.14 billion, up from its previous range of about $1.06 billion to $1.12 billion. Analysts surveyed by FactSet expect $1.09 billion.

The company also said it is launching a $100 million share buyback program that will run through May 2029.

Shares of the company were up 4.6% in pre-bell trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2633451131"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2633451131\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2633451131?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633451131","market":"fut","top_or_hot":-1,"title":"Update: ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Lifts 2026 Outlook","media":"MT Newswires Live","content":"<html><body><p> (Updates with share buyback program and stock movement in the last two paragraphs.)</p><p>ANI Pharmaceuticals (ANIP) reported Q1 adjusted earnings Friday of $2.05 per diluted share, up from $1.70 a year earlier.</p><p>Analysts surveyed by FactSet expected $1.30.</p><p>Net revenue for the quarter ended March 31 was $237.5 million, up from $197.1 million a year earlier.</p><p>Analysts polled by FactSet expected $207.6 million.</p><p>The company said it now expects full-year 2026 adjusted diluted EPS to be between $9.19 and $9.69, compared with its previous guidance for $8.83 to $9.34. Analysts surveyed by FactSet expect $9.07.</p><p>Full-year 2026 net revenue is now projected at $1.08 billion to $1.14 billion, up from its previous range of about $1.06 billion to $1.12 billion. Analysts surveyed by FactSet expect $1.09 billion.</p><p>The company also said it is launching a $100 million share buyback program that will run through May 2029.</p><p>Shares of the company were up 4.6% in pre-bell trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Update: ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Lifts 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpdate: ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Lifts 2026 Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-08 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> (Updates with share buyback program and stock movement in the last two paragraphs.)</p><p>ANI Pharmaceuticals (ANIP) reported Q1 adjusted earnings Friday of $2.05 per diluted share, up from $1.70 a year earlier.</p><p>Analysts surveyed by FactSet expected $1.30.</p><p>Net revenue for the quarter ended March 31 was $237.5 million, up from $197.1 million a year earlier.</p><p>Analysts polled by FactSet expected $207.6 million.</p><p>The company said it now expects full-year 2026 adjusted diluted EPS to be between $9.19 and $9.69, compared with its previous guidance for $8.83 to $9.34. Analysts surveyed by FactSet expect $9.07.</p><p>Full-year 2026 net revenue is now projected at $1.08 billion to $1.14 billion, up from its previous range of about $1.06 billion to $1.12 billion. Analysts surveyed by FactSet expect $1.09 billion.</p><p>The company also said it is launching a $100 million share buyback program that will run through May 2029.</p><p>Shares of the company were up 4.6% in pre-bell trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANIP","symbol_name":"ANI Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2633451131","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633451131","pubTimestamp":1778245822,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ANI Pharmaceuticals  reported Q1 adjusted earnings Friday of $2.05 per diluted share, up from $1.70 a year earlier.Analysts surveyed by FactSet expected $1.30.Net revenue for the quarter ended March 31 was $237.5 million, up from $197.1 million a year earlier.Analysts polled by FactSet expected $207.6 million.The company said it now expects full-year 2026 adjusted diluted EPS to be between $9.19 and $9.69, compared with its previous guidance for $8.83 to $9.34. Analysts surveyed by FactSet expect $9.07.Full-year 2026 net revenue is now projected at $1.08 billion to $1.14 billion, up from its previous range of about $1.06 billion to $1.12 billion. Analysts surveyed by FactSet expect $1.09 billion.The company also said it is launching a $100 million share buyback program that will run through May 2029.Shares of the company were up 4.6% in pre-bell trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ANIP":"ANI Pharmaceuticals, Inc."},"translate_title":"更新：ANI Pharmaceuticals第一季度调整后盈利、收入增长；电梯2026年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANIP":1.5},"content_text":"(Updates with share buyback program and stock movement in the last two paragraphs.)ANI Pharmaceuticals (ANIP) reported Q1 adjusted earnings Friday of $2.05 per diluted share, up from $1.70 a year earlier.Analysts surveyed by FactSet expected $1.30.Net revenue for the quarter ended March 31 was $237.5 million, up from $197.1 million a year earlier.Analysts polled by FactSet expected $207.6 million.The company said it now expects full-year 2026 adjusted diluted EPS to be between $9.19 and $9.69, compared with its previous guidance for $8.83 to $9.34. Analysts surveyed by FactSet expect $9.07.Full-year 2026 net revenue is now projected at $1.08 billion to $1.14 billion, up from its previous range of about $1.06 billion to $1.12 billion. Analysts surveyed by FactSet expect $1.09 billion.The company also said it is launching a $100 million share buyback program that will run through May 2029.Shares of the company were up 4.6% in pre-bell trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}